試卷名稱:114年 - 114 國立臺灣大學_碩士班招生考試:免疫學(A)#125936
年份:114年
科目:研究所、轉學考(插大)◆免疫學
20. CAR-T and Immune checkpoint blockade (ICB) are two breakthroughs in recent years for tumor immunotherapy. Which statement concerning these two approaches is NOT CORRECT?
(A) CAR-T approach bypasses the requirement of recognition of MHC-peptide and 2 signals to activate antigen-specific T cells
(B) The ICB approved for treating cancer patients is to block molecules that transduce inhibitory signals in T cells, not in antigen-presenting cells
(C) CAR-T and ICB both work for solid tumors and leukemia efficiently
(D) The mechanisms for anti-CLT4 and anti-PD-1 ICBs are different; therefore, there is increased therapeutic activity when combining both treatments